Lachgar Amine

Dr. Lachgar Amine


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Revue D'Épidémiologie Et de Santé Publique
Verified
Journal Article
Closed access
LALachgar Amine
Lachgar Amine
MTM.A. Tazi
M.A. Tazi
MAM. Afif
M. Afif
AEA. Er-Raki
A. Er-Raki
TKT. Kebdani
T. Kebdani
NBN. Benjaafar
N. Benjaafar

14 June 2021 in African Journal of Urology
Verified
Journal Article
Open access
PDF file
SRS. Ridai
S. Ridai
CMC. Moustakbal
C. Moustakbal
LALachgar Amine
Lachgar Amine
HJH. Jouhadi
H. Jouhadi
ABA. Benider
A. Benider
FMF. Marnissi
F. Marnissi
Background: Basal cell carcinoma of the prostate is a relatively rare entity. Their evolution is characterized by the frequency of local and/or distant relapses. Due to their rarity, the treatment is not consensual in the literature. We report here a case of Basal cell carcinoma of the prostate in a 40-year-old patient. Case presentation: Our patient initially presented an obstructive lower urinary tract symptoms with a normal initial level of prostate specific antigen (PSA) test (3.5 ng/m). The transurethral resection of the prostate (TURP) was in favor of a prostatic basal cell carcinoma with its specific anatomopathological and immunohistochemical characteristics. The prostatic MRI and thoraco-abdominal CT realized after the TURP revealed a tumoral lesion of the prostatic peripheral zone with extra-capsular extension combined with right seminal vesicle invasion and a suggestion of posterior bladder wall adherence. No evidence of visceral or nodal metastases at this point. Considering the tumor being locally advanced, a concurrent chemoradiotherapy with intensity modulated technique was indicated after a multidisciplinary meeting with a 70 Gy total target dose delivered in 35 fractions and weekly Cisplatin. A year and a half after, he developed a cerebellous metastases revealed by intracranial hypertension with no other visceral lesion and complete local remission with the disappearance of the lower urinary tract symptoms and the pain and the appearance of a prostatic atrophy. The PSA level was still on the upper limit of normal. He underwent metastasectomy, and the anatomopathological study was in favor of a cerebellous metastasis of the known BCC. The patient presented postoperatively paraparesis of lower limbs with balance problems for which he was placed in palliative care with indication of postoperative radiation therapy in case of improvement of his general condition. He did not recover and deceased three months later. Conclusions: The prostatic basal cell carcinoma is a rare aggressive entity often non-evoked at the clinical or radiological stages because of its unspecific appearance. The diagnostic of these tumors is based on histological examination and a large immunohistochemistry panel. Given its scarity, very few data is available for locally advanced non-metastatic stages treated by radiation therapy. We assess here a good local response with concurrent chemoradiation therapy.

30 June 2024 in Otolaryngologia Polska
Verified
Journal Article
Closed access
LALachgar Amine
Lachgar Amine
GNGuy N'Da
Guy N'Da
KNKarima Nouni
Karima Nouni
HKHanan El Kacemi
Hanan El Kacemi
TKTayeb Kebdani
Tayeb Kebdani
KHKhalid Hassouni
Khalid Hassouni
Introduction: We report our experience in the treatment of parotid cancers by radiotherapy delivered with curative intent over a period of 10 years. Aim: The aim of this study was to evaluate the therapeutic results and prognostic factors. Materials and methods: This is a retrospective study of patients with parotid cancer treated with radiotherapy between 2008 and 2017 at the National Institute of Oncology in Rabat. Patients who received adjuvant or exclusive radiotherapy were included in this study. We performed a multivariate analysis for the factors related to locoregional control and overall survival. Results: Initially, 74 patients (45 men and 29 women), at a median age of 57 years. were identified. At the time of diagnosis, 10 (13.6%), 36 (48.6%), and 28 (37.8%) patients were in stage II, III, and IVab, respectively. Sixty patients received adjuvant radiotherapy after parotidectomy and 14 patients received exclusive radiotherapy for an unresectable tumor. At 5 years, the rate of locoregional control and overall survival were 68.2% and 53.7%, respectively. Surgical resection and negative margins were significantly correlated with locoregional control. Lymph node involvement, unresectable tumors, high-grade histological types, and cystic adenoid carcinoma were significantly correlated with poor overall survival. Conclusions: Acceptable long-term results are obtained with surgery combined with radiotherapy. Surgical resection remains essential for parotid cancer, given the disappointing results of treatment with radiotherapy alone.

1 March 2022 in Bulletin du Cancer
Verified
Journal Article
Closed access
LALachgar Amine
Lachgar Amine
SRSara Ridai
Sara Ridai
SMSafaa Mouafik
Safaa Mouafik
HKHajar Kaiss
Hajar Kaiss
NSNadir Sahli
Nadir Sahli
ABAbdelatif Benider
Abdelatif Benider

10 April 2026 in Bulletin du Cancer
Verified
Journal Article
Closed access
LALachgar Amine
Lachgar Amine
IHImane Hassnaoui
Imane Hassnaoui
ENEdith Tatiana Ngbwa
Edith Tatiana Ngbwa
RGRania El Gueddari
Rania El Gueddari
MYMoulay Ali Youssoufi
Moulay Ali Youssoufi
KHKhalid Hassouni
Khalid Hassouni

1 November 2025 in Innovations & Thérapeutiques en Oncologie
Verified
Journal Article
Closed access
PDF file
RLRachida Laraichi
Rachida Laraichi
SSSara Smiti
Sara Smiti
CEChadia Ezzouitina
Chadia Ezzouitina
FCFatima Zahra Chraa
Fatima Zahra Chraa
ISIhsane SKITIOUI
Ihsane SKITIOUI
KHKhalid Hassouni
Khalid Hassouni